Oramed Pharmaceuticals Inc. (TLV:ORMP)
Israel
· Delayed Price · Currency is ILS · Price in ILA 798.80
+10.20 (1.29%)
Apr 2, 2025, 5:24 PM IDT
Oramed Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Cash & Equivalents | 54.42 | 9.06 | 40.46 | 27.46 | - | Upgrade
|
| Short-Term Investments | 87.51 | 152.99 | 115.26 | 118.82 | - | Upgrade
|
| Cash & Short-Term Investments | 141.93 | 162.05 | 155.72 | 146.28 | - | Upgrade
|
| Cash Growth | -12.41% | 4.06% | 6.45% | - | - | Upgrade
|
| Prepaid Expenses | 1.29 | 0.54 | 1.39 | 1.66 | - | Upgrade
|
| Total Current Assets | 143.22 | 162.58 | 157.11 | 147.94 | - | Upgrade
|
| Property, Plant & Equipment | 1.11 | 1.57 | 1.8 | 0.89 | - | Upgrade
|
| Long-Term Investments | 10.91 | 56.37 | 2.7 | 3.88 | - | Upgrade
|
| Other Long-Term Assets | 0.03 | 0.03 | 0.03 | 25.12 | - | Upgrade
|
| Total Assets | 155.28 | 220.55 | 161.64 | 177.82 | - | Upgrade
|
| Accounts Payable | 5.14 | 0.55 | 2.18 | 1.69 | - | Upgrade
|
| Accrued Expenses | - | 1.38 | 1.97 | 2.31 | - | Upgrade
|
| Short-Term Debt | - | 51.01 | - | - | - | Upgrade
|
| Current Portion of Leases | 0.22 | 0.27 | 0.25 | 0.13 | - | Upgrade
|
| Current Unearned Revenue | - | - | 1.34 | 2.7 | - | Upgrade
|
| Other Current Liabilities | 0.33 | - | 0.01 | 0.53 | - | Upgrade
|
| Total Current Liabilities | 5.69 | 53.21 | 5.75 | 7.37 | - | Upgrade
|
| Long-Term Leases | 0.16 | 0.34 | 0.65 | 0.37 | - | Upgrade
|
| Long-Term Unearned Revenue | 4 | 4 | 4 | 3.34 | - | Upgrade
|
| Other Long-Term Liabilities | 0.06 | 0.07 | 0.07 | 0.11 | - | Upgrade
|
| Total Liabilities | 9.93 | 57.66 | 10.49 | 11.21 | - | Upgrade
|
| Common Stock | 0.48 | 0.49 | 0.48 | 0.46 | - | Upgrade
|
| Additional Paid-In Capital | 322.4 | 320.89 | 314.42 | 292.51 | - | Upgrade
|
| Retained Earnings | -176.62 | -157.56 | -163.08 | -126.52 | - | Upgrade
|
| Total Common Equity | 146.27 | 163.82 | 151.81 | 166.45 | - | Upgrade
|
| Minority Interest | -0.92 | -0.93 | -0.66 | 0.16 | - | Upgrade
|
| Shareholders' Equity | 145.35 | 162.89 | 151.16 | 166.61 | - | Upgrade
|
| Total Liabilities & Equity | 155.28 | 220.55 | 161.64 | 177.82 | - | Upgrade
|
| Total Debt | 0.37 | 51.62 | 0.89 | 0.5 | - | Upgrade
|
| Net Cash (Debt) | 141.56 | 112.23 | 154.83 | 149.66 | - | Upgrade
|
| Net Cash Growth | 26.13% | -27.51% | 3.45% | - | - | Upgrade
|
| Net Cash Per Share | 3.47 | 2.77 | 3.97 | 4.03 | - | Upgrade
|
| Filing Date Shares Outstanding | 40.85 | 40.52 | 39.78 | 38.56 | 24.39 | Upgrade
|
| Total Common Shares Outstanding | 39.92 | 40.34 | 39.56 | 38.16 | 24.39 | Upgrade
|
| Working Capital | 137.54 | 109.37 | 151.36 | 140.57 | - | Upgrade
|
| Book Value Per Share | 3.66 | 4.06 | 3.84 | 4.36 | - | Upgrade
|
| Tangible Book Value | 146.27 | 163.82 | 151.81 | 166.45 | - | Upgrade
|
| Tangible Book Value Per Share | 3.66 | 4.06 | 3.84 | 4.36 | - | Upgrade
|
Updated Nov 7, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.